KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Novavax (NVAX) Cost of Revenue (2022 - 2025)

Historic Cost of Revenue for Novavax (NVAX) over the last 10 years, with Q3 2025 value amounting to $21.5 million.

  • Novavax's Cost of Revenue fell 6453.92% to $21.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $87.6 million, marking a year-over-year decrease of 7271.26%. This contributed to the annual value of $202.7 million for FY2024, which is 4102.45% down from last year.
  • As of Q3 2025, Novavax's Cost of Revenue stood at $21.5 million, which was down 6453.92% from $15.3 million recorded in Q2 2025.
  • In the past 5 years, Novavax's Cost of Revenue ranged from a high of $434.6 million in Q3 2022 and a low of $14.1 million during Q1 2025
  • Moreover, its 4-year median value for Cost of Revenue was $55.8 million (2023), whereas its average is $100.0 million.
  • Within the past 5 years, the most significant YoY rise in Novavax's Cost of Revenue was 12419.1% (2023), while the steepest drop was 7942.39% (2023).
  • Over the past 4 years, Novavax's Cost of Revenue (Quarter) stood at $181.8 million in 2022, then fell by 14.74% to $155.0 million in 2023, then crashed by 76.34% to $36.7 million in 2024, then plummeted by 41.38% to $21.5 million in 2025.
  • Its Cost of Revenue stands at $21.5 million for Q3 2025, versus $15.3 million for Q2 2025 and $14.1 million for Q1 2025.